About

Reinventing Drug Discovery

For over 30 years, our mission has been to use the power of science to bring new medicines to patients… over and over again.

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, nearly all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic diseases, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite^® technologies, such as VelocImmune^®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center^®, which is conducting one of the largest genetics sequencing efforts in the world.

Every day, we apply our homegrown technologies and relentless spirit to help people with serious diseases. See what drives us.

2020 was a challenging but inspiring year: from creating a new medicine in record time while advancing a diverse pipeline to delivering needed medicines despite pandemic conditions.

2020 Annual Report

2020 Responsibility Report

Regeneron News: Oct 22nd

Dupixent® (dupilumab) is the First Biologic to Significantly Reduce Itch and Skin Lesions in Phase 3 Trial for Prurigo Nodularis, Demonstrating the Role of Type 2 Inflammation in this Disease

Regeneron News: Oct 20th

FDA Expands Approval of Dupixent® (dupilumab) to Include Children Aged 6 to 11 Years with Moderate-to-severe Asthma

Regeneron News: Oct 14th

FDA Accepts REGEN-COV® (casirivimab and imdevimab) for Priority Review for Treatment and Prophylaxis of COVID-19

Regeneron by the numbers

30+

years of scientific leadership

9K+

employees worldwide

~1.1K+

employees with an MD, PhD or PharmD degree

3^rd

consecutive year as one of Fast Company Best Workplaces for Innovators

ranking in Science magazine's global Top Employer survey for six of the past nine years

3,000+

volunteers for virtual Day for Doing Good 2020

FDA-approved medicines

98%

of our waste diverted from landfill, surpassing our 2025 global responsibility goal

~100%

of drug candidates invented and developed in-house

1.4M+

exomes sequenced to date

175+

peer-reviewed publications in 2020

30+

product candidates in clinical development across multiple therapeutic areas

Honors and awards

Fast Company: Best Workplaces for Innovators, 2021

Great Place To Work: Fortune 100 Best Companies to Work For, 2021

Great Place to Work Ireland: Best Workplaces, 2021

Great Place to Work Ireland: Best Workplaces for Women, 2021

Fast Company: World Changing Ideas (Pandemic Response), 2021

IDEA Pharma: Pharmaceutical Invention Index, 2021

Science: Top Employer, 2020

Fortune: Change the World, 2020

Forbes: JUST Companies, 2020

Dow Jones Sustainability World Index, 2020

Dow Jones Sustainability North American Index, 2020

Newsweek: America’s Most Responsible Companies, 2020

Civic 50: Most Community-Minded Companies in the Nation, 2020

Great Places to Work: Best Workplace in Ireland, 2020

Shingo Institute: The Shingo Prize, 2019

Led by science

We are the only biopharma company founded and led by physician-scientists since the beginning, more than three decades ago. From our first days, science was and remains our central guiding principle. Our leadership includes multiple Nobel Laureates and five members of the National Academy of Sciences, and we are one of the first companies to form a Science and Technology Committee as an integral component of its Board, a practice which has since become industry standard.

Get To Know The Team